Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norepinephrine vs Midodrine/Octreotide in HRS-AKI
NCT04522297Completed
- Sponsor
- National Hepatology and Tropical Medicine Research Institute
- Start
- Apr 2018
- Primary completion
- Jan 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of midodrine and Octreotide long-acting injection in hepatorenal syndrome (HRS) (2 arms), sponsored by National Hepatology and Tropical Medicine Research Institute. Primary endpoint: Full response at 10 days. Started Apr 2018; status: completed.
02
Drugs
midodrineOctreotide long-acting injection
03
Conditions
hepatorenal syndrome (HRS)
Beyond the preview
Go deeper on NCT04522297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522297.